Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Ixekizumab confers efficacy for up to 4 years in moderate-to-severe psoriasis

01 Aug 2018

It appears that the efficacy of ixekizumab treatment in patients with moderate-to-severe psoriasis lasts for up to 4 years, according to a phase II study.

The investigators performed analysis by last observation carried forward involving patients who received ixekizumab 120 mg and then 80 mg subcutaneously once every 4 weeks.

Ninety-three percent of the patients who completed the randomized placebo-controlled trial entered the open-label extension (OLE). There was a 75-percent decrease in the Psoriasis Area Severity Index score in 82 percent of patients at week 208 of the OLE.

Sixty-four percent of patients had a static Physician Global Assessment score of 0 or 1, and 45 percent had a score of 0 at week 208. Compared with baseline, a decrease was observed in the patients’ Dermatology Life Quality Index and Itch visual analogue scale scores. There were also improvements in other efficacy and health outcome measures.

Serious adverse events (AE) were reported in 16.7 percent of patients, and 87 percent had one or more treatment-emergent AE. Serious infections occurred in three patients, while one patient reported two major cardiovascular events.

This study was limited by the lack of a placebo or active comparator, and it was also unblinded.

A previous phase III trial (UNCOVER-3) has found that ixekizumab is well tolerated and yields persistent efficacy through 108 weeks. [J Am Acad Dermatol 2017;77:855-862]

“Ixekizumab has demonstrated improvement in patients with moderate-to-severe psoriasis by selectively targeting interleukin-17A, which is a proinflammatory cytokine that is important in the pathogenesis of psoriasis,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.